Use of Bevacizumab for neurological complications during initial treatment of malignant gliomas;Utilización de bevacizumab en las complicaciones neurológicas durante el tratamiento inicial de los gliomas malignos

Neurologia

Volumn 26, Issue 2, 2011, Pages 74-80

  Arratibel Echarren, I ^a   Albright, K ^a   Dalmau, J ^a   Rosenfeld, M R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Bevacizumab; Corticosteroids; High grade glioma; Oedema; Radiation necrosis; Tumour progression

Indexed keywords

BEVACIZUMAB; CORTICOSTEROID;

ARTICLE; BRAIN EDEMA; CANCER GRADING; CASE REPORT; CYTOREDUCTIVE SURGERY; DRUG EFFICACY; DRUG TOLERABILITY; DRUG USE; GLIOBLASTOMA; HUMAN; NEUROLOGICAL COMPLICATION; RADIATION NECROSIS; STANDARD; TREATMENT RESPONSE; TUMOR GROWTH;

ADULT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; GLIOMA; HUMANS; MALE; MIDDLE AGED;

EID: 79952003331     PISSN: 02134853     EISSN: 15781968     Source Type: Journal    
DOI: 10.1016/j.nrl.2010.05.010     Document Type: Article

References (10)

1. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005, 352:987-996.
2. González J., Kumar A.J., Conrad C.A., Levin V.A. Effect of bevacizumab on radiation necrosis of the brain. Int J Radiat Oncol Biol Phys. 2007, 67:323-326.
3. Batchelor T.T., Sorensen A.G., di Tomaso E., Zhang W.T., Duda D.G., Cohen K.S., et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007, 11:83-95.
4. Zuniga R.M., Torcuator R., Jain R., Anderson J., Doyle T., Ellika S., et al. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol. 2009, 91:329-336.
5. Vredenburgh J.J., Desjardins A., Herndon J.E., Dowell J.M., Reardon D.A., Quinn J.A., et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007, 13:1253-1259.
6. Friedman H.S., Prados M.D., Wen P.Y., Mikkelsen T., Schiff D., Abrey L.E., et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009, 27:4733-4740.
7. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004, 350:2335-2342.
8. Johnson D.H., Fehrenbacher L., Novotny W.F., Herbst R.S., Nemunaitis J.J., Jablons D.M., et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004, 22:2184-2191.
9. Miller K., Wang M., Gralow J., Dickler M., Cobleigh M., Pérez E.A., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007, 357:2666-2676.
10. Yang J.C., Haworth L., Sherry R.M., Hwu P., Schwartzentruber D.J., Topalian S.L., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003, 349:427-434.